Roche and Spark Therapeutics Inc. have again extended the offering period of Roche’s previously announced tender offer to purchase all of the outstanding shares of common stock of Spark for $114.50 per share, subject to the conditions set forth in the offer to purchase dated March 7, 2019.
Pursuant to the agreement and plan of merger, dated as of February 22, 2019, which was previously scheduled to expire at 5 p.m. EST on Wednesday, July 31, 2019, has been extended until 5 p.m. EST on Tuesday, September 3, 2019, unless it is extended further under the circumstances set forth in the merger agreement. All terms and conditions of the offer remain unchanged.
The offer was extended to provide additional time for the U.S. Federal Trade Commission (and the UK Competition and Markets Authority to complete their previously disclosed reviews of Roche’s pending acquisition of Spark. The parties remain committed to the transaction and are working cooperatively and expeditiously with the FTC and the CMA.